Foghorn Therapeutics Inc. (FHTX)
FHTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.85
-5.13% on the day
Market cap
$109.9M
Micro cap
Revenue · 2025
$30.9M
+36.8% on 2024
Net income · 2025
-$74.3M
-240.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | FHTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001822462 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $30.9M |
| Net income | -$74.3M |
| Operating income | -$86.4M |
| Net margin | -240.3% |
| Operating margin | -279.5% |
| Revenue growth | +36.8% |
| Cash | $80.9M |
| Total assets | $198.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-12 |
| Latest annual report | 10-K | 2026-03-11 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-01 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 354 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLLS | Cellectis S.A. | $1.10 | -6.78% | $110.6M |
| VTVT | vTv Therapeutics Inc. | $28.23 | -7.32% | $111.6M |
| CPIX | Cumberland Pharmaceuticals Inc. | $7.17 | +2.43% | $107.4M |
| GNLX | Genelux Corporation | $2.52 | -0.98% | $114.0M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $6.13 | -7.68% | $105.1M |
| COYA | Coya Therapeutics Inc. | $4.47 | -6.96% | $105.0M |
| HURA | TuHURA Biosciences Inc. | $1.81 | -4.74% | $115.3M |
| PDSB | PDS Biotechnology Corporation | $1.60 | +5.26% | $116.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier